Zenosense, Inc. (ZENO) Pursues Early MRSA Detection Device to Battle ‘Multi-Billion Dollar Problem’
Zenosense and Sgenia Group are together focused on developing an advanced MRSA sensor. Both companies are involved in the design and creation of a cost-effective methicillin-resistant staphylococcus aureus (MRSA) detection system which is integral in fighting off what some have referred to as a multi-billion dollar problem. Headquartered in Madrid, Sgenia Group has established Zenon Biosystem, a subsidiary contracted to develop the MRSA device for Zenosense. It is anticipated that the product will appeal to distributor channels and end users due to the rising need for an economical detection solution. MRSA (Methicillin-resistant Staphylococcus aureus) is a result of a strain…